Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care

Opinion
Video

Panelists discuss how while daratumumab-based quadruplet regimens are increasingly becoming the standard of care for patients with transplant-eligible newly diagnosed multiple myeloma (TE NDMM) due to superior efficacy data, certain factors like frailty, comorbidities, and cost considerations may still warrant triplet therapy in select cases.

Video content above is prompted by the following:

  • From your experience, do you believe that daratumumab-based quadruplet induction regimens are the new standard of care for TE NDMM patients?
  • In which patients would you consider induction with a triplet regimen?
Recent Videos
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.

FDA Accepts Linvoseltamab BLA for Review in R/R Multiple Myeloma

Roman Fabbricatore
February 11th 2025
Article

Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Clinical Trials Underestimate HRQOL Burden on R/R Myeloma Population

Clinical Trials Underestimate HRQOL Burden on R/R Myeloma Population

Tim Cortese
February 9th 2025
Article

A retrospective systemic literature review showed that increased lines of therapy led to decreased HRQOL in patients with relapsed/refractory myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease

Roman Fabbricatore
February 4th 2025
Article

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups

Russ Conroy
February 2nd 2025
Article

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.